Key result
Beta blockers remain the primary treatment for preventing life-threatening arrhythmias in congenital long QT syndrome, supplemented by genotype-specific therapies, ICDs, and lifestyle modifications.
Answers are grounded in this paper and cite their sources.
Beta blockers remain the cornerstone of therapy for congenital long QT syndrome, while genetic testing increasingly guides personalized management strategies.
Congenital long QT syndrome (LQTS) is one of the most common cardiac channelopathies and is characterized by prolonged ventricular repolarization and life-threatening arrhythmias. The mortality is high among untreated patients. The identification of several LQTS genes has had a major impact on the management strategy for both patients and family members. An impressive genotype-phenotype correlation has been noted and genotype identification has enabled genotype specific therapies. Beta blockers continue to be the primary treatment for prevention of life threatening arrhythmias in the majority of patients. Other therapeutic options include pacemakers, implantable cardioverter defibrillators, left cardiac sympathetic denervation, sodium channel blocking medications and lifestyle modification.
No takes yet. Share an insight, caveat, or question.
Carter et al. (2008) conducted a review in Long QT syndrome. Beta blockers, ICDs, pacemakers, left cardiac sympathetic denervation was evaluated. Beta blockers remain the primary treatment for preventing life-threatening arrhythmias in congenital long QT syndrome, supplemented by genotype-specific therapies, ICDs, and lifestyle modifications.
Synapse has enriched 10 related papers. Consider them for comparative context: